Literature DB >> 30315507

Current Treatment Strategies and Future Treatment Options for Dravet Syndrome.

Julie Ziobro1, Krista Eschbach2, Joseph E Sullivan3, Kelly G Knupp4.   

Abstract

PURPOSE OF REVIEW: Dravet syndrome is a rare but severe genetic epilepsy that has unique treatment challenges. This is a review of current and future potential treatment options. RECENT
FINDINGS: Treatment for Dravet syndrome should encompass many aspects of the syndrome such as gait, behavior, and nutrition, as well as focus on seizure control. Many sodium channel blockers should be avoided as they are likely to exacerbate seizures. Current options for treatment include valproic acid, clobazam, stiripentol, and ketogenic diet. Testing is underway for several new treatment options with unique mechanisms of action and therapeutic targets, including the serotonin system and genetic modulation. Accurate and early diagnosis of Dravet syndrome will lead to avoidance of medications that may exacerbate seizures. Additionally, a multi-disciplinary approach and careful planning for management of episodes of status epilepticus may lead to improved outcomes. Ongoing research for novel approaches to treatment creates optimism for future improvement in outcomes.

Entities:  

Keywords:  Dravet syndrome; Fenfluramine; SCN1A; Stiripentol

Year:  2018        PMID: 30315507     DOI: 10.1007/s11940-018-0537-y

Source DB:  PubMed          Journal:  Curr Treat Options Neurol        ISSN: 1092-8480            Impact factor:   3.598


  70 in total

1.  Ketogenic diet also benefits Dravet syndrome patients receiving stiripentol: a prospective pilot study.

Authors:  Rima Nabbout; Cristiana Copioli; Mathilde Chipaux; Nicole Chemaly; Isabelle Desguerre; Olivier Dulac; Catherine Chiron
Journal:  Epilepsia       Date:  2011-05-13       Impact factor: 5.864

2.  Clemizole and modulators of serotonin signalling suppress seizures in Dravet syndrome.

Authors:  Aliesha Griffin; Kyla R Hamling; Kelly Knupp; SoonGweon Hong; Luke P Lee; Scott C Baraban
Journal:  Brain       Date:  2017-03-01       Impact factor: 13.501

3.  Optogenetic localization and genetic perturbation of saccade-generating neurons in zebrafish.

Authors:  Peter J Schoonheim; Aristides B Arrenberg; Filippo Del Bene; Herwig Baier
Journal:  J Neurosci       Date:  2010-05-19       Impact factor: 6.167

4.  Incidence of Dravet Syndrome in a US Population.

Authors:  Yvonne W Wu; Joseph Sullivan; Sharon S McDaniel; Miriam H Meisler; Eileen M Walsh; Sherian Xu Li; Michael W Kuzniewicz
Journal:  Pediatrics       Date:  2015-10-05       Impact factor: 7.124

5.  Mortality in Dravet syndrome.

Authors:  Monica S Cooper; Anne Mcintosh; Douglas E Crompton; Jacinta M McMahon; Amy Schneider; Kevin Farrell; Vijeya Ganesan; Deepak Gill; Sara Kivity; Tally Lerman-Sagie; Ailsa McLellan; James Pelekanos; Venkateswaran Ramesh; Lynette Sadleir; Elaine Wirrell; Ingrid E Scheffer
Journal:  Epilepsy Res       Date:  2016-10-26       Impact factor: 3.045

6.  Seizure precipitants in Dravet syndrome: What events and activities are specifically provocative compared with other epilepsies?

Authors:  Nienke E Verbeek; Merel Wassenaar; Jolien S van Campen; Anja Sonsma; Boudewijn Gunning; Nine Knoers; Dick Lindhout; Floor E Jansen; Frans Leijten; Eva H Brilstra; Dorothée Kasteleijn-Nolst Trenité
Journal:  Epilepsy Behav       Date:  2015-05-26       Impact factor: 2.937

7.  Pharmacokinetics of clobazam and N-desmethylclobazam in children with dravet syndrome receiving concomitant stiripentol and valproic Acid.

Authors:  Vincent Jullien; Stéphanie Chhun; Elisabeth Rey; Olivier Dulac; Michel Tod; Catherine Chiron; Gérard Pons
Journal:  Clin Pharmacokinet       Date:  2015-05       Impact factor: 6.447

8.  Stiripentol efficacy and safety in Dravet syndrome: a 12-year observational study.

Authors:  Kenneth A Myers; Paul Lightfoot; Shekhar G Patil; J Helen Cross; Ingrid E Scheffer
Journal:  Dev Med Child Neurol       Date:  2018-02-23       Impact factor: 5.449

9.  Drug screening in Scn1a zebrafish mutant identifies clemizole as a potential Dravet syndrome treatment.

Authors:  Scott C Baraban; Matthew T Dinday; Gabriela A Hortopan
Journal:  Nat Commun       Date:  2013       Impact factor: 14.919

10.  Ketogenic diet effects on 52 children with pharmacoresistant epileptic encephalopathy: A clinical prospective study.

Authors:  Qiong Wu; Hua Wang; Yu Ying Fan; Jun Mei Zhang; Xue Yan Liu; Xiu Ying Fang; Feng Hua Yang; Qing Jun Cao; Ying Qi
Journal:  Brain Behav       Date:  2018-04-18       Impact factor: 2.708

View more
  10 in total

Review 1.  Drug Resistance in Epilepsy: Clinical Impact, Potential Mechanisms, and New Innovative Treatment Options.

Authors:  Wolfgang Löscher; Heidrun Potschka; Sanjay M Sisodiya; Annamaria Vezzani
Journal:  Pharmacol Rev       Date:  2020-07       Impact factor: 25.468

2.  A Phase II Randomized Trial to Explore the Potential for Pharmacokinetic Drug-Drug Interactions with Stiripentol or Valproate when Combined with Cannabidiol in Patients with Epilepsy.

Authors:  Elinor Ben-Menachem; Boudewijn Gunning; Carmen María Arenas Cabrera; Kevan VanLandingham; Julie Crockett; David Critchley; Louise Wray; Bola Tayo; Gilmour Morrison; Manuel Toledo
Journal:  CNS Drugs       Date:  2020-06       Impact factor: 5.749

3.  Mitochondrial Regulation of the Hippocampal Firing Rate Set Point and Seizure Susceptibility.

Authors:  Boaz Styr; Nir Gonen; Daniel Zarhin; Antonella Ruggiero; Refaela Atsmon; Neta Gazit; Gabriella Braun; Samuel Frere; Irena Vertkin; Ilana Shapira; Michal Harel; Leore R Heim; Maxim Katsenelson; Ohad Rechnitz; Saja Fadila; Dori Derdikman; Moran Rubinstein; Tamar Geiger; Eytan Ruppin; Inna Slutsky
Journal:  Neuron       Date:  2019-04-29       Impact factor: 17.173

4.  In vivo, in vitro and in silico correlations of four de novo SCN1A missense mutations.

Authors:  Andreea Nissenkorn; Yael Almog; Inbar Adler; Mary Safrin; Marina Brusel; Milit Marom; Shayel Bercovich; Daniel Yakubovich; Michal Tzadok; Bruria Ben-Zeev; Moran Rubinstein
Journal:  PLoS One       Date:  2019-02-08       Impact factor: 3.240

5.  Efficacy and safety of adjunctive antiseizure medications for dravet syndrome: A systematic review and network meta-analysis.

Authors:  Jianhua Wu; Liu Zhang; Xi Zhou; Jiajun Wang; Xiangyi Zheng; Hankun Hu; Dongfang Wu
Journal:  Front Pharmacol       Date:  2022-08-31       Impact factor: 5.988

6.  Zebrafish studies identify serotonin receptors mediating antiepileptic activity in Dravet syndrome.

Authors:  Aliesha L Griffin; Priyadarshini Jaishankar; Jean-Marc Grandjean; Steven H Olson; Adam R Renslo; Scott C Baraban
Journal:  Brain Commun       Date:  2019-08-01

Review 7.  Dravet Syndrome: An Overview.

Authors:  Arsalan Anwar; Sidra Saleem; Urvish K Patel; Kogulavadanan Arumaithurai; Preeti Malik
Journal:  Cureus       Date:  2019-06-26

8.  Fenfluramine for Treatment-Resistant Seizures in Patients With Dravet Syndrome Receiving Stiripentol-Inclusive Regimens: A Randomized Clinical Trial.

Authors:  Rima Nabbout; Arun Mistry; Sameer Zuberi; Nathalie Villeneuve; Antonio Gil-Nagel; Rocio Sanchez-Carpintero; Ulrich Stephani; Linda Laux; Elaine Wirrell; Kelly Knupp; Catherine Chiron; Gail Farfel; Bradley S Galer; Glenn Morrison; Michael Lock; Anupam Agarwal; Stéphane Auvin
Journal:  JAMA Neurol       Date:  2020-03-01       Impact factor: 18.302

Review 9.  Clinical implications of trials investigating drug-drug interactions between cannabidiol and enzyme inducers or inhibitors or common antiseizure drugs.

Authors:  Philip N Patsalos; Jerzy P Szaflarski; Barry Gidal; Kevan VanLandingham; David Critchley; Gilmour Morrison
Journal:  Epilepsia       Date:  2020-09-12       Impact factor: 5.864

10.  Cannabidiol in conjunction with clobazam: analysis of four randomized controlled trials.

Authors:  Boudewijn Gunning; Maria Mazurkiewicz-Bełdzińska; Richard F M Chin; Hari Bhathal; Charlotte Nortvedt; Eduardo Dunayevich; Daniel Checketts
Journal:  Acta Neurol Scand       Date:  2020-10-22       Impact factor: 3.209

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.